About sana biotechnology inc - SANA
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
SANA At a Glance
Sana Biotechnology, Inc.
188 East Blaine Street
Seattle, Washington 98102
| Phone | 1-206-701-7914 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -244,166,000.00 | |
| Sector | Health Technology | Employees | 142 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SANA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 6.748 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.426 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.082 |
SANA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,719,478.873 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SANA Liquidity
| Current Ratio | 1.889 |
| Quick Ratio | 1.889 |
| Cash Ratio | 1.811 |
SANA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -52.637 |
| Return on Equity | -118.704 |
| Return on Total Capital | -101.844 |
| Return on Invested Capital | -87.676 |
SANA Capital Structure
| Total Debt to Total Equity | 49.018 |
| Total Debt to Total Capital | 32.894 |
| Total Debt to Total Assets | 18.481 |
| Long-Term Debt to Equity | 39.733 |
| Long-Term Debt to Total Capital | 26.663 |